TrimRX | Bioavailability Explained: Why Injection Works Better Than Oral (Sometimes)

Introduction

Bioavailability is one of the most important pharmacology concepts in modern medicine. It refers to the fraction of an administered dose that reaches systemic circulation in active form. Intravenous injection has 100% bioavailability by definition. Every other route loses some fraction of the dose along the way.

For peptide drugs like semaglutide and tirzepatide, oral bioavailability is typically below 1%. Injection produces 70 to 90% bioavailability subcutaneously. This is why GLP-1 drugs are almost all injected. Rybelsus®, the oral semaglutide tablet, gets around the problem with absorption enhancers, but bioavailability remains low.

Understanding bioavailability explains why drug developers make the choices they do, why dosing differs between formulations, and why some drugs cannot be made oral despite efforts to do so.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does Bioavailability Mean?

Bioavailability is a measure of how much of a drug actually reaches the bloodstream in active form. For an IV injection, 100% of the drug enters circulation directly. For other routes, the drug must cross barriers like the gut wall, the skin, or mucous membranes, and survive metabolism along the way.

Quick Answer: Bioavailability is the fraction of drug reaching systemic circulation

The standard measure is the area under the concentration-time curve (AUC). The AUC after oral dosing divided by the AUC after IV dosing of the same compound gives the absolute oral bioavailability.

For acetaminophen, oral bioavailability is about 85%. For oral semaglutide, it is about 1%. The difference matters because it determines how much drug needs to be administered to produce a therapeutic effect.

Why Do Most Peptide Drugs Need Injection?

Peptides are made of amino acids linked by peptide bonds. The digestive system contains enzymes specifically designed to break these bonds: pepsin in the stomach, trypsin and chymotrypsin in the small intestine, and various peptidases in the gut wall.

If you swallow a peptide, most of it gets digested into individual amino acids before it can be absorbed. The fraction that reaches the bloodstream intact is tiny.

Subcutaneous or intramuscular injection bypasses the digestive system entirely. The peptide enters tissue, gets absorbed through capillaries, and reaches systemic circulation with high bioavailability. This is why all marketed GLP-1 injectables use subcutaneous administration.

How Does Oral Semaglutide Work?

Rybelsus is oral semaglutide developed by Novo Nordisk and approved by the FDA in 2019. It uses an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, abbreviated SNAC, to allow some semaglutide absorption from the stomach.

SNAC works by locally raising stomach pH around the tablet, which prevents protein degradation in that microenvironment. It also disrupts the gastric mucus layer and may have direct effects on epithelial permeability. The result is that a small fraction of the semaglutide can cross the gastric mucosa and enter circulation.

Even with SNAC, bioavailability is only about 0.4 to 1%. Rybelsus tablets contain 3, 7, or 14 mg of semaglutide to deliver the equivalent of much smaller injectable doses. The PIONEER trial program established efficacy comparable to injectable semaglutide for diabetes.

What Is First-pass Metabolism?

First-pass metabolism is the breakdown of orally absorbed drugs by the liver before they reach systemic circulation. After absorption from the gut, blood flows through the portal vein directly to the liver. Hepatic enzymes can metabolize a significant fraction of the drug before it reaches the rest of the body.

For some drugs, first-pass metabolism is so extensive that oral administration is impractical. Nitroglycerin, for example, has near-zero oral bioavailability because of complete hepatic clearance. It must be given sublingual or transdermal to bypass the first pass.

GLP-1 peptides do not have a major first-pass metabolism problem because they are largely degraded in the gut before reaching the portal vein. The barrier is digestive, not hepatic.

Why Is Subcutaneous Injection Chosen Over IV?

For long-acting peptides like semaglutide and tirzepatide, subcutaneous injection provides a sustained release profile that matches the once-weekly dosing pattern. The drug forms a depot in the subcutaneous tissue and is gradually absorbed over days.

IV administration of these drugs would produce a sharp peak followed by elimination over the drug half-life. This would still work pharmacologically but would require a different formulation and would not improve outcomes.

Subcutaneous injection is also easier for patient self-administration. Modern pen devices make weekly injection straightforward. IV requires venous access and clinical setting.

How Does Drug Molecular Weight Affect Absorption?

Molecular weight is one factor in absorption. Small molecules under about 500 daltons can often diffuse across cell membranes and gut barriers reasonably well. Larger molecules struggle, particularly water-soluble ones.

Semaglutide has a molecular weight of about 4,113 daltons. Tirzepatide is similar at 4,813 daltons. These are far larger than the typical small-molecule drug, which is why oral absorption is so poor without enhancement.

Liposomal formulations, nanoparticle delivery, and absorption enhancers like SNAC are different strategies for getting large molecules across the gut barrier. None has achieved high bioavailability for peptides, but enhancement to 1 to 5% can be enough for some drugs.

What Other Routes Are Used for Peptide Delivery?

Inhalation has been tried, with insulin pulmonary delivery (Afrezza) being the main success. Bioavailability is moderate, around 25 to 30% relative to subcutaneous insulin. Acceptance has been limited.

Transdermal patches work for some small molecules but not for peptides, which are too large to cross intact skin.

Microneedle patches are an emerging technology that may allow peptide delivery without traditional injection. Several companies are working on microneedle GLP-1 formulations.

Intranasal delivery works for some peptides like oxytocin and calcitonin. Bioavailability is typically 5 to 20%. This has not been pursued aggressively for GLP-1 drugs.

Key Takeaway: Oral semaglutide (Rybelsus) bioavailability is about 1%

How Does Dose Differ Between Routes?

When the same drug is administered by different routes, the dose typically scales inversely with bioavailability. Oral semaglutide doses (3, 7, 14 mg daily) are much higher than subcutaneous doses (0.25 to 2.4 mg weekly) precisely because oral absorption is so poor.

For tirzepatide, only subcutaneous formulations have been developed to date. Oral tirzepatide programs are reportedly in early development but have not reached clinical trials.

Compounded versions of these drugs are typically subcutaneous, matching the absorption profile of the approved branded products.

How Does TrimRx Use This in Dosing?

TrimRx uses subcutaneous compounded semaglutide and tirzepatide, matching the route of branded products. Dosing follows the titration protocols established in STEP and SURMOUNT trials.

A free assessment quiz starts the clinical review. The personalized treatment plan adjusts dose based on tolerability and response, using the predictable subcutaneous absorption profile.

What Is the Role of Formulation in Bioavailability?

The formulation around a drug, including buffers, stabilizers, and absorption enhancers, can significantly affect bioavailability. The same active ingredient in different formulations can produce different blood levels and clinical effects.

For injectable peptides, the formulation typically includes phosphate buffers, preservatives, and tonicity agents. These components do not significantly affect absorption but do affect stability, pH, and injection site comfort.

For oral semaglutide, the SNAC formulation is critical. Without SNAC, oral semaglutide bioavailability would be essentially zero. The formulation enables the therapeutic effect entirely.

How Is Bioavailability Measured?

Bioavailability studies typically compare blood concentration profiles after different routes of administration in the same individuals. Crossover designs reduce inter-individual variability.

The pharmacokinetic parameters of interest include Cmax (peak concentration), Tmax (time to peak), AUC (area under the curve), and half-life. Each parameter informs different aspects of drug behavior.

For new drug approvals, bioavailability data is required to support dosing recommendations. For generic approvals, bioequivalence to the reference product must be demonstrated within FDA-specified statistical bounds.

What Is the Difference Between Subcutaneous and Intramuscular Injection?

Subcutaneous injection deposits drug in the fatty layer between skin and muscle. Absorption is gradual through capillaries in the subcutaneous tissue, typically reaching peak blood levels over hours to days.

Intramuscular injection deposits drug into muscle tissue, which has richer blood supply and faster absorption. Peak blood levels are typically reached more quickly than subcutaneous, often within 30 minutes to a few hours.

For GLP-1 medications, subcutaneous administration is preferred because the gradual absorption profile complements the long drug half-life. Intramuscular administration would produce higher peaks without significant clinical benefit.

Why Do Some Drugs Require Empty Stomach Administration?

Food can affect drug absorption through multiple mechanisms. Food slows gastric emptying, dilutes drug in stomach contents, changes stomach pH, and competes for absorption pathways.

For oral semaglutide (Rybelsus), the SNAC absorption enhancer requires the right gastric environment to work. Food interferes with the enhancement, dropping bioavailability further. The drug must be taken at least 30 minutes before any food or other oral medications.

For subcutaneous GLP-1 medications, food does not affect absorption. The drug bypasses the digestive system entirely, so food intake timing is irrelevant to medication dosing.

Bottom line: First-pass hepatic metabolism reduces oral bioavailability for many drugs

FAQ

Why Cannot Semaglutide Be Made Into a Pill That Works as Well as the Injection?

Peptide drugs are broken down by digestive enzymes. Oral semaglutide (Rybelsus) achieves only about 1% bioavailability even with absorption enhancers.

Is Rybelsus as Effective as Ozempic®?

PIONEER trials showed comparable A1C reductions for diabetes when doses were matched for biological effect. Weight loss outcomes are also similar at equivalent doses.

What Is the Difference Between IV and Subcutaneous?

IV delivers the drug directly into the bloodstream with 100% bioavailability and rapid peak. Subcutaneous deposits the drug in tissue for gradual absorption with high but not 100% bioavailability.

Does Injection Technique Affect Bioavailability?

Injecting too deep or too shallow can change absorption rates. Proper subcutaneous technique provides reliable and consistent absorption.

Are Oral Peptides the Future?

For some drugs, yes. Absorption enhancement, nanoparticle delivery, and other technologies continue to improve. For GLP-1, injection will likely remain the standard for higher doses.

Why Are Some Drugs Sublingual?

Sublingual absorption bypasses the gut and first-pass liver metabolism. This works well for some small molecules but is generally not enough for peptides.

Can Compounded Peptides Be Made Oral?

Some compounding pharmacies make oral or sublingual peptide preparations. Bioavailability is typically very low, and clinical effectiveness has not been established for most.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Bioavailability Explained: Why Injection Works Better Than Oral (Sometimes)

Table of Contents